Since Kyowa Kirin Pharmaceutical Research's (KKR) founding in 1988, KKR has acted as Kyowa Hakko Kirin's (KHK) agent to facilitate the company's pharmaceutical business development efforts in North America.
KKR actively seeks early stage discovery and translational research collaborations with academia and industry. We focus on novel technologies in immunology and welcome the opportunity to explore collaborative opportunities in this area.
By transferring the EIE (External Innovation Engine) function from BioWa to KKR, KKR serves as an oversea window for the Research and Development Division of KHK and actively seeks external opportunities in products at discovery through pre-clinical stages and in novel innovative technologies to enrich KHK's research product pipeline in the areas of oncology, immunology (inflammation, autoimmune diseases), nephrology, and central nervous system. KKR also considers strategic collaborations and/or partnerships with pharmaceuticals, biotech, and academia. KKR can work more directly and efficiently with the Open Innovation Department at KHK to accelerate its external innovation activities. Furthermore, KKR's lab activities focusing on exploratory and translational research can also be utilized for external opportunities.
For more information on KHK's R&D activities, please visit Kyowa Hakko Kirin Global Site.
For additional information on partnering opportunities, please contact the Business Development Department at email@example.com.